Although the benefits outweigh the potential harms of all gadolinium-based contrast agents used for MRI scans, the FDA said these agents can remain in the body for months—even years—after a procedure.
The FDA, which issued a class warning, said there were steps that can minimize the problem of gadolinium remaining in various parts of the body, including the brain.